March 2, 2021
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease Series A-2 led by Hatteras Venture Partners and Biohaven Donnie…
February 18, 2021
FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - - Myeloprotective efficacy of COSELA resulted…
February 18, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan to conduct combination studies with BeiGene's anti-PD-1 antibody tislelizumab BOSTON & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb. 17, 2021-- Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of…
October 1, 2020
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs
BIAL Biotech to be based in Cambridge, Massachusetts and will be a ResearchCenter of Excellence dedicated to genetically-defined Parkinson’s disease• LTI-291 clinical program and other research programs in Parkinson's diseaseacquired…
August 21, 2020
Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins…
August 19, 2020
Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight Time SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today…
August 14, 2020
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness DURHAM, N.C.,…
July 9, 2020
Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients
– Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments – – Kymera to retain option during clinical development to participate equally in US…
June 15, 2020
Shattuck Labs Announces Closing of $118 Million Series B Financing
Financing will advance two ARC™ clinical programs and expand pipeline development -- DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage…
May 27, 2020
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk…